Terms: = Colorectal cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Prognosis
4 results:
1. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma.
Park YY; An CH; Oh ST; Chang ED; Lee J
Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377
[TBL] [Abstract] [Full Text] [Related]
2. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract] [Full Text] [Related]
3. Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II colorectal cancer: A Prospective Multicenter Trial.
Yamamoto H; Murata K; Fukunaga M; Ohnishi T; Noura S; Miyake Y; Kato T; Ohtsuka M; Nakamura Y; Takemasa I; Mizushima T; Ikeda M; Ohue M; Sekimoto M; Nezu R; Matsuura N; Monden M; Doki Y; Mori M
Clin Cancer Res; 2016 Jul; 22(13):3201-8. PubMed ID: 26831719
[TBL] [Abstract] [Full Text] [Related]
4. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel cancer Screening Programme.
Morris EJ; Whitehouse LE; Farrell T; Nickerson C; Thomas JD; Quirke P; Rutter MD; Rees C; Finan PJ; Wilkinson JR; Patnick J
Br J Cancer; 2012 Aug; 107(5):757-64. PubMed ID: 22850549
[TBL] [Abstract] [Full Text] [Related]
